Does the media prefer TARS or ELAN?

In the previous week, Elanco Animal Health had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 16 mentions for Elanco Animal Health and 15 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Elanco Animal Health's score of 1.41 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Elanco Animal Health 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or TARS?

In the previous week, Axsome Therapeutics had 17 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 32 mentions for Axsome Therapeutics and 15 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Axsome Therapeutics' score of 0.92 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 20 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer TARS or RDY?

In the previous week, Tarsus Pharmaceuticals had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 4 mentions for Dr. Reddy's Laboratories. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dr. Reddy's Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRNX or TARS?

In the previous week, Tarsus Pharmaceuticals had 6 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 9 mentions for Crinetics Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Crinetics Pharmaceuticals' score of 1.50 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor LQDA or TARS?

In the previous week, Tarsus Pharmaceuticals had 8 more articles in the media than Liquidia. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 7 mentions for Liquidia. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Liquidia's score of 0.59 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Tarsus Pharmaceuticals (TARS) Competitors

$71.76 -0.16 (-0.22%)

As of 08/28/2026 04:00 PM Eastern

Compare

TARS vs. ELAN, AXSM, RDY, CRNX, and LQDA

Should you buy Tarsus Pharmaceuticals stock or one of its competitors? Tarsus Pharmaceuticals's main competitors and comparable companies include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), and Liquidia (LQDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tarsus Pharmaceuticals compare to Elanco Animal Health?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Tarsus Pharmaceuticals currently has a consensus price target of $90.50, suggesting a potential upside of 26.11%. Elanco Animal Health has a consensus price target of $29.09, suggesting a potential upside of 20.41%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Tarsus Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Elanco Animal Health had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 16 mentions for Elanco Animal Health and 15 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Elanco Animal Health's score of 1.41 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Elanco Animal Health	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Elanco Animal Health has a net margin of -3.96% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Elanco Animal Health's return on equity of 8.13% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Elanco Animal Health	-3.96%	8.13%	3.99%

Tarsus Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A
Elanco Animal Health	$4.72B	2.56	-$232M	-$0.41	N/A

Summary

Elanco Animal Health beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, Axsome Therapeutics had 17 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 32 mentions for Axsome Therapeutics and 15 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Axsome Therapeutics' score of 0.92 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	20 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Axsome Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	16.33	-$183.17M	-$3.75	N/A
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Axsome Therapeutics' net margin of -24.68%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Axsome Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Axsome Therapeutics presently has a consensus target price of $267.60, indicating a potential upside of 34.46%. Tarsus Pharmaceuticals has a consensus target price of $90.50, indicating a potential upside of 26.11%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Summary

Axsome Therapeutics beats Tarsus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Tarsus Pharmaceuticals had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 4 mentions for Dr. Reddy's Laboratories. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A
Dr. Reddy's Laboratories	$3.58B	2.84	$456M	$0.44	27.66

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Tarsus Pharmaceuticals presently has a consensus price target of $90.50, suggesting a potential upside of 26.11%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Tarsus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tarsus Pharmaceuticals has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Crinetics Pharmaceuticals currently has a consensus price target of $81.00, indicating a potential downside of 4.53%. Tarsus Pharmaceuticals has a consensus price target of $90.50, indicating a potential upside of 26.11%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

In the previous week, Tarsus Pharmaceuticals had 6 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 9 mentions for Crinetics Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Crinetics Pharmaceuticals' score of 1.50 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tarsus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Crinetics Pharmaceuticals has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats Crinetics Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Tarsus Pharmaceuticals had 8 more articles in the media than Liquidia. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 7 mentions for Liquidia. Tarsus Pharmaceuticals' average media sentiment score of 1.62 beat Liquidia's score of 0.59 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

64.5% of Liquidia shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tarsus Pharmaceuticals has higher revenue and earnings than Liquidia. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.27	-$68.92M	$1.37	49.41
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A

Liquidia has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Liquidia's return on equity of 149.65% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Liquidia currently has a consensus target price of $98.08, suggesting a potential upside of 44.90%. Tarsus Pharmaceuticals has a consensus target price of $90.50, suggesting a potential upside of 26.11%. Given Liquidia's higher possible upside, equities research analysts clearly believe Liquidia is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Summary

Liquidia beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARS vs. The Competition

Export

Metric	Tarsus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.16B	$12.21B	$7.24B	$12.93B
Dividend Yield	N/A	2.62%	2.54%	10.96%
P/E Ratio	-65.83	780.29	271.50	25.38
Price / Sales	6.98	756.07	624.00	96.54
Price / Cash	N/A	95.73	79.29	54.21
Price / Book	9.08	11.93	12.95	6.14
Net Income	-$66.42M	$2.81B	$3.46B	$347.93M
7 Day Performance	-1.29%	0.52%	-0.11%	-0.78%
1 Month Performance	22.62%	6.37%	8.32%	5.60%
1 Year Performance	22.50%	6.09%	24.64%	15.64%

Tarsus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARS Tarsus Pharmaceuticals	3.7585 of 5 stars	$71.76 -0.2%	$90.50 +26.1%	+23.4%	$3.16B	$451.36M	N/A	50	News Coverage Positive News
ELAN Elanco Animal Health	4.6931 of 5 stars	$23.51 -0.4%	$29.09 +23.8%	+30.8%	$11.74B	$5.02B	N/A	9,400	Positive News
AXSM Axsome Therapeutics	4.2495 of 5 stars	$215.91 -0.2%	$267.60 +23.9%	+63.5%	$11.31B	$776.57M	N/A	380	Analyst Revision
RDY Dr. Reddy's Laboratories	1.7915 of 5 stars	$12.16 +0.4%	N/A	-14.5%	$10.15B	$3.58B	27.63	27,527	News Coverage Analyst Upgrade
CRNX Crinetics Pharmaceuticals	1.6717 of 5 stars	$84.79 +0.0%	$81.00 -4.5%	+176.8%	$8.99B	$42.16M	N/A	210	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARS) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. ELAN, AXSM, RDY, CRNX, and LQDA

How does Tarsus Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Tarsus Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

How does Tarsus Pharmaceuticals compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. ELAN, AXSM, RDY, CRNX, and LQDA

How does Tarsus Pharmaceuticals compare to Elanco Animal Health?

Do analysts rate TARS or ELAN?

Does the media prefer TARS or ELAN?

Which has more risk and volatility, TARS or ELAN?

Do institutionals and insiders have more ownership in TARS or ELAN?

Is TARS or ELAN more profitable?

Which has preferable valuation and earnings, TARS or ELAN?

Summary

How does Tarsus Pharmaceuticals compare to Axsome Therapeutics?

Does the media favor AXSM or TARS?

Do insiders & institutionals have more ownership in AXSM or TARS?

Which has preferable earnings and valuation, AXSM or TARS?

Is AXSM or TARS more profitable?

Which has more risk and volatility, AXSM or TARS?

Do analysts prefer AXSM or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Does the media prefer TARS or RDY?

Which has higher earnings & valuation, TARS or RDY?

Is TARS or RDY more profitable?

Do analysts rate TARS or RDY?

Which has more risk & volatility, TARS or RDY?

Do institutionals & insiders hold more shares of TARS or RDY?

Summary

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Do analysts recommend CRNX or TARS?

Is CRNX or TARS more profitable?

Does the media favor CRNX or TARS?

Which has better valuation & earnings, CRNX or TARS?

Do institutionals & insiders believe in CRNX or TARS?

Which has more risk & volatility, CRNX or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Liquidia?

Does the media favor LQDA or TARS?

Do insiders & institutionals have more ownership in LQDA or TARS?

Which has higher earnings & valuation, LQDA or TARS?

Which has more risk & volatility, LQDA or TARS?

Is LQDA or TARS more profitable?

Do analysts rate LQDA or TARS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools